MAINZ BIOMED NV (MYNZ)
NL0015000LC2 - Common Stock
MYNZ gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 576 industry peers in the Biotechnology industry. Both the profitability and financial health of MYNZ have multiple concerns. MYNZ is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year MYNZ has reported negative net income.
MYNZ had a negative operating cash flow in the past year.
In the past 5 years MYNZ always reported negative net income.
MYNZ had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -170.63%, MYNZ is not doing good in the industry: 87.78% of the companies in the same industry are doing better.
With a Return On Equity value of -809.21%, MYNZ is not doing good in the industry: 82.37% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -170.63% | ||
| ROE | -809.21% | ||
| ROIC | N/A |
ROA(3y)-139.16%
ROA(5y)-127.77%
ROE(3y)-393.42%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 57.11%, MYNZ belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
MYNZ's Gross Margin has improved in the last couple of years.
MYNZ does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.46%
GM growth 5YN/A
2. Health
2.1 Basic Checks
MYNZ does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYNZ has been increased compared to 1 year ago.
The debt/assets ratio for MYNZ is higher compared to a year ago.
2.2 Solvency
MYNZ has an Altman-Z score of -9.67. This is a bad value and indicates that MYNZ is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.67, MYNZ is not doing good in the industry: 76.61% of the companies in the same industry are doing better.
A Debt/Equity ratio of 0.36 indicates that MYNZ is not too dependend on debt financing.
The Debt to Equity ratio of MYNZ (0.36) is worse than 71.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.67 |
ROIC/WACCN/A
WACC6.28%
2.3 Liquidity
A Current Ratio of 0.97 indicates that MYNZ may have some problems paying its short term obligations.
With a Current ratio value of 0.97, MYNZ is not doing good in the industry: 88.66% of the companies in the same industry are doing better.
MYNZ has a Quick Ratio of 0.97. This is a bad value and indicates that MYNZ is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.91, MYNZ is not doing good in the industry: 88.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.91 |
3. Growth
3.1 Past
MYNZ shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.96%, which is quite good.
The Revenue has grown by 68.96% in the past year. This is a very strong growth!
The Revenue has been growing by 22.26% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
MYNZ is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.58% yearly.
The Revenue is expected to grow by 156.06% on average over the next years. This is a very strong growth
EPS Next Y50.45%
EPS Next 2Y26.69%
EPS Next 3Y18.58%
EPS Next 5Y14.58%
Revenue Next Year56.23%
Revenue Next 2Y113.27%
Revenue Next 3Y139.89%
Revenue Next 5Y156.07%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
MYNZ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MYNZ is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MYNZ's earnings are expected to grow with 18.58% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.69%
EPS Next 3Y18.58%
5. Dividend
5.1 Amount
No dividends for MYNZ!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MAINZ BIOMED NV
NASDAQ:MYNZ (7/3/2024, 7:23:03 PM)
After market: 0.3312 0 (-1.16%)0.3351
0 (-1.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.34M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -170.63% | ||
| ROE | -809.21% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 57.11% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.36 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.97 | ||
| Quick Ratio | 0.91 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)12.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y50.45%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)68.96%
Revenue growth 3Y22.26%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y